Iperion Life Sciences Becomes Part of Deloitte
Deloitte has announced its acquisition of Iperion Life Sciences Consultancy (Vlijmen, The Netherlands). As of May 1, Iperion is operating as Iperion — a Deloitte business. The business will run as part of Deloitte’s Risk Advisory function. Iperion’s co-founder Frits Stulp will serve as a partner within the Deloitte Risk operation, and his counterpart Karel Bastiaanssen has committed to supporting the integration and growth of Iperion in the coming years. The home base of Iperion will remain in Vlijmen, the Netherlands.
Iperion was founded six years ago with the aim of boosting innovation in life sciences by promoting the structuring and digitizing of regulated data required for the approval and monitoring of medicines.
Speaking for Iperion, Frits Stulp said: “Deloitte and Iperion have been collaborating on innovative digitization projects at pharmaceutical companies for years. The integration with Deloitte is a logical next step to further shape the ambitions and growth strategy of both organizations in this area by, among other things, joining our efforts to implement the data standard ISO IDMP”.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
